Peptides: The Molecule Making Waves

What Even Is a Peptide?

Quick biology lesson — and then we move on, because this isn't a science journal. Peptides are short chains of amino acids. Proteins, which you've definitely heard of, are made of these same building blocks — just in much longer chains. Think of peptides as proteins with a word count limit. Small enough to be synthesised in a lab, precise enough to hit very specific biological targets.

They've been in medicine for decades — insulin, used by diabetics since the 1920s, is a peptide. But recent advances in synthesis technology and drug delivery have opened up a completely new era. We can now design peptides that do things we couldn't dream of twenty years ago: suppress appetite through gut hormone pathways, stimulate muscle protein synthesis, cross the blood-brain barrier to influence cognition, and even deliver chemotherapy payloads directly to tumour cells.

The GLP-1 drugs — Ozempic, Wegovy, Mounjaro — proved the concept to the world. They're peptide-based medicines targeting the glucagon-like peptide-1 receptor. They work. Spectacularly. And they turned their makers into the most valuable pharmaceutical companies in Europe almost overnight.

But GLP-1 Is Already Priced In — So What's Next?

Here's the thing about Novo Nordisk (NVO) and Eli Lilly (LLY): the market has already given them the valuation of a company that has solved obesity. Those stocks have re-rated dramatically, and buying them today means you believe the growth story continues at pace. That's a reasonable view — but the asymmetric opportunity is elsewhere.

The peptide universe extends far beyond appetite suppression. Here are the areas I'm watching:

Beyond the Clinic: What Peptides Are Already Doing in the Real World

The demand for peptides is not being driven solely by physicians prescribing them for diagnosed conditions. There is an enormous parallel market — wellness, performance, aesthetics, longevity optimisation — that is already consuming these compounds at scale, largely through unregulated channels. Understanding this demand is essential to understanding why the regulatory stakes are so high, and why the commercial opportunity extends well beyond pharmaceutical company earnings.

Skin and appearance. GHK-Cu (copper tripeptide) is already available as a topical cream — regulated differently from its injectable form — and has strong biochemical evidence behind it: improved complexion, increased collagen and elastin synthesis, measurable reduction in visible ageing markers, and benefits in rosacea management. Melanotan-2, a melanocortin receptor agonist, produces a deep tan with minimal UV exposure — a different mechanism entirely, but illustrative of just how broad the peptide toolkit is.

Sleep, recovery, and circadian health. DSIP (Delta Sleep-Inducing Peptide) regulates circadian rhythm and promotes restorative sleep architecture. Epithalon works on telomerase activation and has a secondary role in circadian regulation. Selank calms the nervous system roughly an hour before sleep, promoting the deep delta brainwaves associated with physical recovery. Growth hormone secretagogues, when dosed at night, directly improve sleep quality as a mechanism — not just a side effect.

Energy and physical performance. MOTS-C has been described by clinicians as "exercise in a vial" — it upregulates mitochondrial ATP production and VO2 max, essentially improving the body's energy-conversion efficiency. For the biohacker and performance athlete community, this is enormously appealing without any of the regulatory complexity of anabolic steroids.

Body composition. Tesamorelin, already commercially available by prescription, specifically targets and strips visceral fat — the metabolically dangerous abdominal fat that is notoriously resistant to diet and exercise. Distinct from GLP-1s, which produce broad caloric restriction, tesamorelin works through a growth hormone pathway. Bodybuilders have used it for competition cutting for years.

Cognitive performance. Semax (intranasal) and C-Max are used for focus, mental sharpness, and cognitive connectivity — originally studied in TBI and stroke recovery contexts, now repurposed by the performance-oriented crowd. Silicon Valley's obsession with peptide stacks is not incidental; the cognitive enhancement use case is a significant driver of demand.

Sexual function. PT-141 (bremelanotide) is already commercially available with a prescription and improves sexual response without systemic hormonal effects. Melanotan-2 produces strong pro-erectile effects as a secondary mechanism. These applications represent a substantial and under-discussed portion of the demand driving the grey market.

The investment implication is straightforward: this is not a niche clinical market waiting to be discovered. It is a large, active, paying consumer market currently operating without quality control, without standardised dosing, and without a regulated domestic supply chain. The moment that changes — which the July 2026 FDA review could trigger — that demand does not create itself. It redirects from grey-market vials with no oversight into a licensed, compounded, physician-prescribed supply chain. That transition is what creates the commercial moment.

The Regulatory Catalyst: 19 Peptides Were Banned. Now They're Coming Back.

Here is a piece of background that most investors don't know — and that matters enormously for how you position. In 2023, the FDA quietly reclassified 19 peptide compounds used by compounding pharmacies, moving them from a legal "can compound" list to a banned category. Overnight, clinicians who had been prescribing BPC-157, TB-500, epithalon, and others for years lost access. Patients lost access. The official reason: insufficient safety data from formal FDA approval trials.

What made this controversial: there was no surge in adverse events, no clinical disaster that triggered the ban. The compounds had been widely used with a strong real-world safety record. RFK Jr. has since characterised the 2023 move as illegal, and the current administration has signalled reversal.

The catalyst is specific and near-term: in July 2026, the FDA is scheduled to consider restoring seven of these peptides — including BPC-157, TB-500, MOTS-C, epithalon, Semax, and DSIP — back to legal compoundable status. If that happens, it opens a regulated domestic supply chain for compounds that are already in high demand via an unregulated gray market. That is the kind of regime change that creates investable moments.

Meanwhile, major pharmaceutical companies have signed multi-billion dollar deals with AI-assisted peptide development firms to fast-track proprietary peptide products through formal approval pathways. The regulatory pendulum is swinging — and capital is moving with it.

Source: FDA moves toward easing restrictions on certain peptides — BioPharma Dive, 16 April 2026. Note: the FDA action is an advisory committee meeting; the outcome of the review is not guaranteed.

1. Sarcopenia & Muscle Preservation

Here's the ugly irony of GLP-1 drugs: while they work brilliantly for weight loss, a significant portion of that weight comes from muscle mass, not just fat. As populations age and GLP-1 usage scales into the hundreds of millions, muscle wasting becomes a parallel epidemic. Peptides targeting muscle protein synthesis — including growth hormone secretagogues and myostatin inhibitors — are the natural complement. This is an enormous unmet need and an early-stage opportunity.

MOTS-C, one of the peptides the FDA is evaluating this July, has been described by clinicians as "exercise in a vial" — it upregulates ATP production and VO2 max via mitochondrial pathways. And coming slightly further down the pipeline: a new class of monoclonal antibody-based myostatin inhibitors (bimagromab from Lilly, aretosumab, travogumab) specifically designed to preserve lean muscle during aggressive GLP-1-induced caloric restriction. The investor read here is straightforward: the GLP-1 market already exists; the muscle-preservation market is being born as a direct consequence.

2. Oncology: Antibody-Drug Conjugates & Peptide Therapeutics

Peptides can be engineered to bind selectively to cancer cell receptors, delivering toxic payloads with far greater precision than traditional chemotherapy. The field of peptide-drug conjugates (PDCs) is following the same logic as the antibody-drug conjugates (ADCs) that made AstraZeneca and Daiichi Sankyo so interesting. Earlier stage, but the mechanism is validated.

3. Cognitive Health & Brain-Penetrant Peptides

Getting molecules across the blood-brain barrier has historically been one of pharma's greatest challenges. A new generation of engineered peptides is overcoming this — with early applications in Alzheimer's, depression, and cognitive performance. The longevity crowd is already deeply interested. The institutional investor community is barely paying attention yet.

Among the peptides under FDA review this July, several operate squarely in the cognitive and circadian space. Semax (intranasal, 7-amino-acid peptide) was originally studied in Russia after traumatic brain injury and stroke, showing faster recovery and upregulation of cognitive connectivity factors. Epithalon targets telomerase — the enzyme that helps maintain telomere length, one of the better-characterised markers of cellular ageing — with additional evidence of improved circadian regulation. DSIP (Delta Sleep-Inducing Peptide) has shown benefits in sleep architecture and rhythm regulation. These are not household names yet. They're the early signals.

The Manufacturing Bottleneck: The Structural Advantage Nobody Talks About

Novo Nordisk cannot make Ozempic fast enough. That is not a drug problem — that is a manufacturing problem. Peptide synthesis at scale is technically complex, capital-intensive, and takes years to build out. The companies that own this capacity — the contract development and manufacturing organisations (CDMOs) — are sitting on a structural pricing advantage that will persist for a decade.

The key players in peptide CDMO manufacturing include Bachem (listed in Switzerland — fitting given my Zurich base), PolyPeptide Group, and Lonza. These aren't household names. They don't have the marketing budgets of Pfizer. But they are absolutely essential to every GLP-1 drug that gets produced, and every next-generation peptide therapeutic that follows.

If Novo Nordisk is the iPhone, Bachem is the TSMC. And we all remember what happened to TSMC's valuation when everyone realised it was non-negotiable infrastructure.

The Longevity Angle

Zoom out for a moment. The entire peptide thesis sits inside the longevity mega-trend: the structural demand for longer, healthier lives from ageing populations in developed markets. This isn't a fad. Demographics don't reverse. The cohort of people turning 65 over the next twenty years is the largest in human history, in the wealthiest countries on earth, with the healthcare spending habits to match.

Peptides address multiple longevity pillars simultaneously: weight management, metabolic health, muscle preservation, cognitive function, and oncology. There is arguably no single drug class better positioned at the intersection of ageing, technology, and unmet medical need.